gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Colony stimulating factor 3

G-CSF, granulocyte colony stimulating factor, Filgrastim
The protein encoded by this gene is a cytokine that controls the production, differentiation, and function of granulocytes. The active protein is found extracellularly. Alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, May 2010] (from NCBI)
Top mentioned proteins: CsF, HAD, CAN, Interleukin-6, AGE
Papers on G-CSF
Critically Ill Patient Due to Pneumonitis Secondary to the Use of Filgrastim.
New
Guerrero et al., Madrid, Spain. In Am J Ther, Feb 2016
UNASSIGNED: Filgrastim is a granulocyte colony-stimulating factor commonly used in the prophylaxis and treatment of neutropenia associated with chemotherapy in cancer patients.
Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
New
Lang et al., Ulm, Germany. In Support Care Cancer, Feb 2016
UNASSIGNED: The recombinant human granulocyte colony-stimulating factor (G-CSF) known as filgrastim (Tevagrastim(®), Ratiograstim(®), Biograstim(®)) in Europe (approved in 2008) and tbo-filgrastim (Granix(®)) in the USA (approved in 2012; Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel) is indicated to reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Review
New
Samuel et al., Princeton, United States. In J Oncol Pharm Pract, Feb 2016
Here, we perform a systematic review assessing the comparative effectiveness of prophylaxis with a long-acting G-CSF (pegfilgrastim) versus short-acting G-CSFs (filgrastim, lenograstim, and filgrastim biosimilars) in cancer patients in real-world clinical settings.
Delayed application of the haematopoietic growth factors G-CSF/SCF and FL reduces neonatal excitotoxic brain injury.
New
Griesmaier et al., Innsbruck, Austria. In Brain Res, Feb 2016
The effect of haematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF) and flt-3 ligand (FL) on neonatal brain injury is controversially discussed.
Interpreting febrile neutropenia rates from randomized controlled trials for consideration of primary prophylaxis in the real world: A systematic review and meta-analysis.
Review
New
Chan et al., Toronto, Canada. In Ann Oncol, Jan 2016
BACKGROUND: Guidelines recommend primary prophylaxis (PP) with granulocyte colony stimulating factors (G-CSF) for patients above a febrile neutropenia (FN) risk threshold of 20%.
Mechanisms for T cell tolerance induced with granulocyte colony-stimulating factor.
Review
New
Sun et al., Shijiazhuang, China. In Mol Immunol, Jan 2016
UNASSIGNED: Granulocyte colony-stimulating factor (G-CSF) has been widely accepted as a mediator of T cell tolerance.
Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial.
New
Impact
Wang et al., Fuzhou, China. In J Clin Oncol, Jan 2016
PATIENTS AND METHODS: We randomly assigned 206 patients undergoing alloHSCT to receive once-daily subcutaneous GM-CSF (5 to 7 μg/kg per day), granulocyte colony-stimulating factor (G-CSF; 5 to 7 μg/kg per day), or a combination of G-CSF and GM-CSF (2 to 3 μg/kg per day each).
SB203580 increases G-CSF production via a stem-loop destabilizing element in the 3' untranslated region in macrophages independently of its effect on p38 MAPK activity.
New
Lu et al., Taipei, Taiwan. In J Biomed Sci, Dec 2015
BACKGROUND: Granulocyte-colony stimulating factor (G-CSF) is a major regulator of the production and survival of neutrophils.
Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
New
Nakagawa et al., Tokyo, Japan. In Radiat Oncol, Dec 2015
No prophylactic treatment with granulocyte colony stimulating factor was administered.
Neutrophil ageing is regulated by the microbiome.
New
Impact
Frenette et al., New York City, United States. In Nature, Oct 2015
Aged neutrophils upregulate CXCR4, a receptor allowing their clearance in the bone marrow, with feedback inhibition of neutrophil production via the IL-17/G-CSF axis, and rhythmic modulation of the haematopoietic stem-cell niche.
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.
New
Impact
de Visser et al., Amsterdam, Netherlands. In Nature, Jul 2015
We mechanistically demonstrate that interleukin (IL)-1β elicits IL-17 expression from gamma delta (γδ) T cells, resulting in systemic, granulocyte colony-stimulating factor (G-CSF)-dependent expansion and polarization of neutrophils in mice bearing mammary tumours.
The importance of the granulocyte-colony stimulating factor in oncology.
Review
Oprean et al., Cluj-Napoca / Kolozsvár, Romania. In Clujul Med, 2014
Granulocyte-colony stimulating factor (G-CSF) is a glycoprotein, the second CSF, sharing some common effects with granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and interleukin-5 (IL-5).
Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Review
Vehreschild et al., Köln, Germany. In Cochrane Database Syst Rev, 2014
We included two trials in the review, one with 40 breast cancer patients receiving high-dose chemotherapy and G-CSF compared to antibiotics, a second one evaluating 155 patients with small-cell lung cancer receiving GM-CSF or antibiotics.We judge the overall risk of bias as high in the G-CSF trial, as neither patients nor physicians were blinded and not all included patients were analysed as randomised (7 out of 40 patients).
The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice.
Impact
Worthen et al., Philadelphia, United States. In Nat Med, 2014
Antibiotic exposure of dams reduced the number of interleukin-17 (IL-17)-producing cells in the intestine and production of granulocyte colony-stimulating factor (G-CSF).
Anticytokine autoantibody-associated immunodeficiency.
Review
Impact
Browne, Bethesda, United States. In Annu Rev Immunol, 2013
Other anticytokine autoantibodies may contribute to an infectious phenotype such as anti-granulocyte colony stimulating factor and anti-IFN-α autoantibodies, although the strength of the association is less clear.
Decreased soluble TGF-β1, Tie-2, and angiopoietins serum levels in bone marrow after treating healthy donors with granulocyte colony-stimulating factor.
GeneRIF
Sun et al., Shijiazhuang, China. In Transfus Apher Sci, 2012
Decreased soluble TGF-beta1, Tie-2, and angiopoietins serum levels in bone marrow after treating healthy donors with granulocyte colony-stimulating factor.
Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling.
GeneRIF
Ferrara et al., San Francisco, United States. In J Biol Chem, 2012
Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling.
Endogenous granulocyte colony-stimulating factor: a biomarker in acute ischemic stroke.
GeneRIF
Liu et al., Taiwan. In Biomarkers, 2012
Elevated plasma GCSF concentration was positively correlated with the severity of ischemic stroke
Granulocyte colony-stimulating factor-producing ascending colon cancer as indicated by histopathological findings: report of a case.
GeneRIF
Inoue et al., Ōsaka, Japan. In Osaka City Med J, 2011
Case Report: diagnosis of G-CSF-producing ascending colon cancer.
[Expression of granulocyte colony stimulating factor in patients with non-small cell lung cancer and its clinicopathological significance].
GeneRIF
Shi et al., Beijing, China. In Zhonghua Bing Li Xue Za Zhi, 2011
Non-small cell lung cancer specimens with G-CSF expression exhibited poor differentiation, remarkable atypia, prominent necrosis and infiltration of tumor mass by neutrophils or emperipolesis.
share on facebooktweetadd +1mail to friends